AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · IEX Real-Time Price · USD

5.71

-0.22 (-3.71%)

At close: Dec 29, 2023, 4:00 PM

5.88

+0.17 (2.98%)

After-hours: Dec 29, 2023, 7:44 PM EST

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018
Revenue	485.42	375.2	233.16	11.61	8.83
Revenue Growth (YoY)	29.38%	60.92%	1907.88%	31.49%	-
Gross Profit	485.42	375.2	233.16	11.61	8.83
Selling, General & Admin	66.76	48.76	15.75	4.01	2.86
Research & Development	107.88	62.06	29.39	10.11	5.8
Other Operating Expenses	94.28	59.97	31.98	1.6	0.92
Operating Expenses	268.91	170.79	77.12	15.73	9.58
Operating Income	216.51	204.41	156.03	-4.12	-0.75
Interest Expense / Income	4.05	6.08	6.81	0.21	0.21
Other Expense / Income	-26.63	-20.82	-8.61	-2.12	-1.27
Pretax Income	239.1	219.15	157.83	-2.21	0.31
Income Tax	80.58	65.69	38.92	0	0
Net Income	158.52	153.46	118.92	-2.21	0.31
Net Income Growth	3.29%	29.05%	-	-	-
Shares Outstanding (Basic)	285	276	159	151	149
Shares Outstanding (Diluted)	315	318	263	151	171
Shares Change	-1.09%	20.96%	73.88%	-11.68%	-
EPS (Basic)	0.56	0.56	0.53	-0.01	-
EPS (Diluted)	0.50	0.48	0.45	-0.01	-
EPS Growth	4.17%	6.67%	-	-	-
Free Cash Flow	206.7	186.13	13.02	-1.3	-1.74
Free Cash Flow Per Share	0.72	0.68	0.08	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	44.60%	54.48%	66.92%	-35.45%	-8.53%
Profit Margin	32.66%	40.90%	51.00%	-19.04%	3.50%
Free Cash Flow Margin	42.58%	49.61%	5.58%	-11.22%	-19.73%
Effective Tax Rate	33.70%	29.97%	24.66%	-	-
EBITDA	276.25	242.48	169.92	-0.16	1.44
EBITDA Margin	56.91%	64.63%	72.88%	-1.33%	16.29%
Depreciation & Amortization	33.1	17.25	5.27	1.85	0.92
EBIT	243.14	225.23	164.64	-2	0.52
EBIT Margin	50.09%	60.03%	70.62%	-17.24%	5.90%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).